At a glance
- Originator Morphochem AG
- Developer Deinove
- Class Obesity therapies
- Mechanism of Action Protein-tyrosine-phosphatase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Obesity; Type 2 diabetes mellitus
Most Recent Events
- 01 Dec 2005 Morphochem AG has been acquired by Biovertis AG
- 19 Sep 2002 Preclinical trials in Obesity in Germany (unspecified route)
- 19 Sep 2002 Preclinical trials in Type-2 diabetes mellitus in Germany (unspecified route)